Picture of Abeona Therapeutics logo

ABEO Abeona Therapeutics Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapMomentum Trap

Momentum

Relative Strength (%)
1m+9.57%
3m+39.68%
6m+66.39%
1yr+137.59%
Volume Change (%)
10d/3m+57.05%
Price vs... (%)
52w High-15.54%
50d MA+19.78%
200d MA+60.31%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)n/a
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value14.04
Price to Tang. Book14.04
Price to Free Cashflown/a
Price to Sales59.48
EV to EBITDAn/a

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-93.19%
Return on Equity-260.6%
Operating Margin-1346.71%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Abeona Therapeutics EPS forecast chart

Profile Summary

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cell and gene therapies for life-threatening diseases. The Company’s lead clinical program is EB-101, an autologous, engineered cell therapy in development for recessive dystrophic epidermolysis bullosa (RDEB). Its development portfolio also features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with unmet medical needs. The Company’s next generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its fully integrated cell and gene therapy Good Manufacturing Practice (cGMP) manufacturing facility produced EB-101 for the pivotal Phase III VIITAL study and is capable of clinical and potential commercial production of AAV-based gene therapies. EB-101 is an autologous, engineered cell therapy in which a functioning COL7A1 gene is inserted into a patient’s own skin cells (keratinocytes) using a retrovirus.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
June 22nd, 1989
Public Since
September 19th, 1980
No. of Shareholders
248
No. of Employees
84
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Capital Market
Shares in Issue
27,355,037

ABEO Share Price Performance

Upcoming Events for ABEO

Abeona Therapeutics Inc Annual Shareholders Meeting

Q1 2024 Abeona Therapeutics Inc Earnings Release

Abeona Therapeutics Inc Annual Shareholders Meeting

Q2 2024 Abeona Therapeutics Inc Earnings Release

Similar to ABEO

Picture of 180 Life Sciences logo

180 Life Sciences

us flag iconNASDAQ Capital Market

Picture of ABVC Biopharma logo

ABVC Biopharma

us flag iconNASDAQ Capital Market

Picture of Acesis Holdings logo

Acesis Holdings

us flag iconNASDAQ Capital Market

Picture of Achieve Life Sciences logo

Achieve Life Sciences

us flag iconNASDAQ Capital Market

Picture of Aclarion logo

Aclarion

us flag iconNASDAQ Capital Market

FAQ